FLUCONAZOLO SUN Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

fluconazolo sun

sun pharmaceutical industries (europe) b.v. - fluconazolo - fluconazolo

TEDIM Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

tedim

dymalife pharmaceutical s.r.l. - fluconazolo - fluconazolo

TRIMIKOS Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

trimikos

euro-pharma s.r.l. - fluconazolo - fluconazolo

FLUKIMEX Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

flukimex

theramex ireland limited - fluconazolo - fluconazolo

TruScient Unione Europea - italiano - EMA (European Medicines Agency)

truscient

zoetis belgium sa - dibotermina alfa - proteine ​​morfogenetiche dell'osso - cani - agente osteoinduttivo per l'uso nel trattamento delle fratture dell'osso lungo in aggiunta alla terapia chirurgica standard con riduzione della frattura aperta nei cani.

Dupixent Unione Europea - italiano - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti per dermatiti, esclusi i corticosteroidi - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

FLUCONAZOLO FIDIA 10CPS 100MG Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

fluconazolo fidia 10cps 100mg

fidia farmaceutici spa - fluconazolo - capsule - " 100 mg capsule " 10 capsule